Glucocorticoids employ the monomeric glucocorticoid receptor to potentiate vitamin D(3) and parathyroid hormone–induced osteoclastogenesis

Glucocorticoid (GC) therapy decreases bone mass and increases the risk of fractures. We investigated interactions between the GC dexamethasone (DEX) and the bone resorptive agents 1,25(OH)(2)-vitamin D(3) (D3) and parathyroid hormone (PTH) on osteoclastogenesis. We observed a synergistic potentiatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Conaway, H. Herschel, Henning, Petra, Lie, Antia, Tuckermann, Jan, Lerner, Ulf H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Federation of American Societies for Experimental Biology 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894088/
https://www.ncbi.nlm.nih.gov/pubmed/31675485
http://dx.doi.org/10.1096/fj.201802729RRR

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894088/
https://www.ncbi.nlm.nih.gov/pubmed/31675485
http://dx.doi.org/10.1096/fj.201802729RRR

Ejemplares similares